A Phase II Clinical Study on Apatinib Plus Vinorelbine in Refractory HER2-Negative Breast Cancer and its Metabolic Implications of Drug Resistance
Apatinib combined with vinorelbine is effective and safe in patients with locally advanced or metastatic refractory HER2-negative breast cancer. The findings of this study contribute to a better understanding of the metabolic effect of apatinib and vinorelbine therapy.
Authors
- La Zou
- Shengchun Liu (ORCID: https://orcid.org/0000-0002-9933-3643)
- Xiaohua Zeng (ORCID: https://orcid.org/0000-0001-5810-8055)
- Deng Pan (ORCID: https://orcid.org/0000-0002-9293-3566)
- Jing Wu (ORCID: https://orcid.org/0000-0002-6416-005X)
- Xianjun Tang
- Xiaoyu Liu (ORCID: https://orcid.org/0009-0004-2165-0210)
Institutions
- Chongqing University (CN)
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- Chongqing Cancer Hospital (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Current Cancer Drug Targets
- Published
- 2024-10-02
- DOI
- https://doi.org/10.2174/0115680096303785240822155217
- Citations
- 1
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 0.28